A Tiny Biotech Says Its Ebola Drug Beat Remdesivir in the Lab
Nasdaq 23 Sep · 19:00

A Tiny Biotech Says Its Ebola Drug Beat Remdesivir in the Lab

The result comes from cell-based tests and a single AI design cycle. The company says it will fund what comes next through government grants rather than new shares — and that an approved drug could carry a voucher worth up to $180 million.

Read the story
Latest
How we work

Every article names the filing or release it came from. Read the source before acting on anything here.

Company in focus Sponsored
Predictiv AI CSE:PAI FWB:7IT

Vertical AI software for logistics, healthcare and aviation.

The AI company working where the real money is made See the full profile

Predictiv AI has paid PennyStocks.News for this placement. It is advertising, not editorial coverage, and nothing here is investment advice.

Find them before we write about them.
Live screens — most active, gainers, losers and most volatile, US and Canada.
Open screener